- Home
- AMSC vs ZYME Comparison
AMSC vs ZYME Comparison
Compare AMSC & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMSC | ZYME |
|---|---|---|
| Founded | 1987 | 2003 |
| Country | United States | United States |
| Employees | 400 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2012 | 2022 |
Fundamental Metrics
Financial Performance| Metric | AMSC | ZYME |
|---|---|---|
| Price | $42.85 | $23.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $52.00 | $38.90 |
| AVG Volume (30 Days) | ★ 1.3M | 588.7K |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1806.25 | 33.33 |
| EPS | ★ 3.05 | N/A |
| Revenue | $900,000.00 | ★ $105,965,000.00 |
| Revenue This Year | $34.98 | $183.10 |
| Revenue Next Year | $21.38 | N/A |
| P/E Ratio | $13.18 | ★ N/A |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $24.87 | $11.86 |
| 52 Week High | $70.49 | $29.75 |
Technical Indicators
Market Signals| Indicator | AMSC | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 45.43 | 41.46 |
| Support Level | $28.57 | $22.28 |
| Resistance Level | $63.48 | $23.66 |
| Average True Range (ATR) | 3.31 | 0.89 |
| MACD | -0.54 | -0.05 |
| Stochastic Oscillator | 38.30 | 31.33 |
Price Performance
Historical ComparisonAbout AMSC American Superconductor Corporation
American Superconductor Corp generates the ideas, technologies, and solutions that meet the world's demand for smarter, cleaner, and energy. Through its Windtec Solutions, the company enables manufacturers to launch wind turbines quickly, effectively, and profitably. Through its Gridtec Solutions, the company provides engineering planning services and grid systems that optimize network reliability, efficiency, and performance. The company's segment includes Grid and Wind. It generates maximum revenue from the Grid segment.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.